122.95
-0.50
(-0.41%)
At close: January 31 at 7:14:37 PM GMT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 9 | 4 | 16 | 14 |
| Avg. Estimate | 7.58 | 4.58 | 35.11 | 18.05 |
| Low Estimate | 5.29 | 1.54 | 28.58 | 9.17 |
| High Estimate | 9.92 | 7.29 | 40.96 | 23.4 |
| Year Ago EPS | 13.07 | 14.37 | 42.53 | 35.11 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 7 | 3 | 15 | 14 |
| Avg. Estimate | 3.97B | 3.07B | 16.56B | 9.93B |
| Low Estimate | 3.13B | 1.57B | 14.34B | 6.39B |
| High Estimate | 5.07B | 3.9B | 17.72B | 13.76B |
| Year Ago Sales | 5.94B | 6.65B | 20.36B | 16.56B |
| Sales Growth (year/est) | -33.20% | -53.80% | -18.70% | -40.00% |
Earnings History
| Currency in USD | 12/31/2021 | 3/31/2022 | 6/30/2022 | 9/30/2022 |
|---|---|---|---|---|
| EPS Est. | 7.99 | 9.32 | 6.99 | 4.59 |
| EPS Actual | 13.07 | 14.37 | 6.36 | 7.11 |
| Difference | 5.08 | 5.05 | -0.63 | 2.52 |
| Surprise % | 63.60% | 54.20% | -9.00% | 54.90% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Current Estimate | 7.58 | 4.58 | 35.11 | 18.05 |
| 7 Days Ago | 7.93 | 4.83 | 32.35 | 17.51 |
| 30 Days Ago | 7.74 | 4.8 | 32.22 | 17.68 |
| 60 Days Ago | 7.91 | 4.13 | 34.95 | 19.28 |
| 90 Days Ago | 7.78 | 4.22 | 34.47 | 19.78 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 7 | 3 |
| Up Last 30 Days | 1 | -- | 8 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 4 | 2 | 1 | 5 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 0A3M.IL | -42.00% | -68.10% | -17.40% | -48.60% |
| S&P 500 | 9.91% | 10.33% | 14.01% | 13.75% |
Upgrades & Downgrades
| Initiated | Truist Securities: Buy | 1/10/2025 |
| Initiated | Wells Fargo: Overweight | 12/11/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 11/27/2024 |
| Maintains | JP Morgan: Neutral to Neutral | 11/26/2024 |
| Upgrade | Evercore ISI Group: In-Line to Outperform | 11/19/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 11/18/2024 |
Related Tickers
B1MR34.SA BioMarin Pharmaceutical Inc.
186.90
0.00%
REGN34.SA Regeneron Pharmaceuticals, Inc.
65.74
-1.81%
BM8.MU Biomarin Pharmaceutical Inc
61.58
+0.95%
ALSEN.PA Sensorion SA
0.6280
+1.62%
MRNA.VI Moderna, Inc.
39.45
-2.18%
IDIA.SW Idorsia Ltd
0.7040
-1.61%
PLRX Pliant Therapeutics, Inc.
10.75
+0.84%
RAPT RAPT Therapeutics, Inc.
1.1400
0.00%
NRIX Nurix Therapeutics, Inc.
19.71
-1.52%
FOLD Amicus Therapeutics, Inc.
9.58
-0.62%